Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease

R.F. Buckley, P. Maruff, D. Ames, P. Bourgeat, Ralph Martins, C.L. Masters, S. Rainey-Smith, Nicola Lautenschlager, C.C. Rowe, G. Savage, V.L. Villemagne, K.A. Ellis

    Research output: Contribution to journalArticle

    68 Citations (Scopus)

    Abstract

    © 2016 The Alzheimer's AssociationIntroduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high ß-amyloid burden (CN Aß+). Methods Fifty-eight CN Aß+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aß+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aß+, more sensitive measures may be required to detect early subtle cognitive change.
    Original languageEnglish
    Pages (from-to)796-804
    Number of pages9
    JournalAlzheimer's and Dementia
    Volume12
    Issue number7
    Early online date4 Feb 2016
    DOIs
    Publication statusPublished - Jul 2016

    Fingerprint Dive into the research topics of 'Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease'. Together they form a unique fingerprint.

    Cite this